A Prospective Study on ¹⁸F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.

ABSTRACT: ¹⁸F-DCFPyL (2-(3-{1-carboxy-5-[(6-¹⁸F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of ¹⁸F-DCFPyL in the setting of biochemical recurrence of prostate cancer. Methods: Subjects with prostate cancer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prospective study. The subjects underwent ¹⁸F-DCFPyL PET/CT imaging. The localization and number of lesions were recorded. The uptake characteristics of the 5 most active lesions were measured. A pre- and posttest questionnair

SUBMITTER: Rousseau E 

PROVIDER: S-EPMC6836862 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature